12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

Isis Pharmaceuticals, GlaxoSmithKline deal

Isis said it amended a 2010 deal with GlaxoSmithKline and now will receive $2.5 million upfront and is eligible to receive a $7.5 million milestone payment triggered by the start of a Phase II/III trial of ISIS-TTRRx to treat familial amyloid polyneuropathy (FAP). Isis expects to start the trial later this year. Isis is also...

Read the full 262 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >